Maintaining Investments in New Innovation Act

Key Points

• This bill changes how long certain high-tech medicines can stay on the market before the government can negotiate lower prices for Medicare. It specifically targets 'advanced drug products' that use gene-targeting technology to treat diseases by changing how genes work.
• Currently, these types of drugs can be chosen for price negotiations after being on the market for 7 years. This bill would push that timeline back to 11 years, giving drug companies an extra four years to sell the medicine at their own chosen price before the government steps in.
• The goal is to encourage companies to keep inventing new treatments for rare or difficult diseases. Supporters believe that because these drugs are very expensive to create, companies need more time to earn back the money they spent on research and development.
• The main trade-off is that Medicare and the people who use it might have to wait longer for lower prices on these specific treatments. Because gene therapies are often among the most expensive medicines available, delaying negotiations could keep government healthcare spending higher for a longer period.

Impact Analysis

Govbase has not yet run an impact analysis on this legislation.